
FDA approves phase 1/2 clinical trial with ABX196 in patients with liver cancer ABX196 to be tested in combination with checkpoint inhibitor nivolumab to treat hepatocellular carcinoma
May 14, 2019
LA JOLLA, CA The U.S. Food and Drug Administration has approved an investigational new drug (IND) application for a phase 1/2 clinical trial of ABX196, a liver cancer therapy developed in the laboratory of Scripps Research Professor Luc Teyton, MD, PhD, and licensed to French pharmaceutical company Abivax.
The FDA approval allows Abivax testing of ABX196 in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. ABX196 showed potent efficacy against HCC in preclinical testing.
The translation of basic research discoveries to the clinic is the greatest achievement we can hope for as clinician scientists. says Teyton, who is also a member of Abivax's Scientific Advisory Board. The use of ABX196 in the context of immunotherapy has been shown to be beneficial in multiple animal models of cancer, but the results with hepatocellular carcinoma are spectacular. We are looking forward to impacting the disease in patients, especially given the limitations of current therapies.
The open IND allows Abivax to test ABX196 in combination with nivolumab (Opdivo, Bristol-Myers Squibb), a checkpoint inhibitor, in a first phase 1/2 clinical trial to treat patients with HCC. The initial dose-escalation phase of the study will be conducted at the Scripps MD Anderson Cancer Center in San Diego, California, USA; additional leading cancer centers in the U.S. will be involved in the subsequent expansion phase of the study. The first patient is expected to be enrolled this summer.
We are thrilled to have been given the green light by FDA for our U.S. study. says Hartmut J. Ehrlich, MD, chief executive officer of Abivax. This open IND allows Abivax, in collaboration with leading key opinion leaders at internationally renowned U.S. cancer centers of excellence, to explore the clinical potential of our iNKT agonist ABX196 to broaden and potentiate the activity of the checkpoint inhibitor nivolumab. Based on its unique mechanism of action and exciting preclinical data in several cancer models, we believe ABX196 is a promising immunotherapeutic product candidate for patients with liver cancer that may also have potential in other cancers.
ABX196 is a synthetic glycolipid agonist of invariant natural killer T cells (iNKT) in a liposomal formulation. A phase 1 clinical trial conducted by Abivax in healthy volunteers has been completed and demonstrated safety and tolerability as well as a potent activation of iNKT cells. ABX196, both alone and in combination with a checkpoint inhibitor, showed a statistically highly significant therapeutic effect in reducing tumor growth as measured by MRI and increasing survival in mice with HCC. Abivax holds exclusive rights to ABX196 from Scripps Research, the University of Chicago, and Brigham Young University.
Despite the recent introduction of checkpoint inhibitors, hepatocellular carcinoma continues to be a substantial therapeutic challenge, as only about 20 percent of the treated patients show a response to these new drugs says Darren Sigal, MD, program director of GI Oncology at Scripps Clinic and Scripps MD Anderson Cancer Center in San Diego, and principal investigator of the study. While checkpoint inhibitors block a do not attack me' signal on cancer cells, ABX196 activates iNKT cells, a subpopulation of lymphocytes that is critical for mounting an effective immune response. The synergy between these two molecules carries substantial promise for improved outcomes for patients with this deadly cancer.
Checkpoint inhibitors like nivolumab are a leading class of therapeutic monoclonal antibodies that block certain endogenous proteins (PD-1/PDL-1) made by immune cells, such as T cells, as well as some cancer cells. These proteins effectively hijack the immune system, causing it to keep immune responses in check and preventing T cells from killing cancer cells. When these proteins are blocked, the brakes on the immune system are released and T cells are able to kill cancer cells much more efficiently. In some cancers, treatment with checkpoint inhibitors has been highly efficacious. However, due to the tumor micro-environment in other cancers, such as HCC, checkpoint inhibitors can have difficulties exerting their effects. ABX196 is intended as a drug that will potentiate the efficacy of checkpoint inhibitors by activating iNKT cells to kill tumor cells.
HCC is the most common form (75 to 90 percent) of primary liver cancer in adults. It typically occurs in the setting of chronic liver inflammation and/or cirrhosis and is closely linked to chronic viral infection such as hepatitis B or C, exposure to toxins such as alcohol, and to certain diseases such as non-alcoholic steatohepatitis (NASH).
The incidence of and deaths related to HCC are increasing in the United States and globally due to hepatitis B and C virus infections, as well as NASH. Prevalence data from 2018 show a total of 79,000 cases of HCC in the U.S. and G5 Europe (Germany, France, Italy, Spain and the UK), with 67,000 new cases, and a total of 260,000 cases in China with 338,000 new cases. Globally, there were 841,000 new cases of liver cancer (ranking it sixth of all reported cancers) and 782,000 fatalities (ranking it fourth) in 2018.
Currently, the American Cancer Society reports five-year survival rates in the U.S. of 31 percent for localized HCC, 11 percent for regional, and 2 percent for distant or metastatic, indicating a clear unmet medical need for improved therapies for HCC.
Cancer Immunology & Microbiology Teyton, Luc
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
18/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
18/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
18/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
18/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
18/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
18/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
18/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
18/11/2026
SMPTE, the home for media professionals, technologists and engineers, today announced the publication of an engineering report with the summarized results of an...
17/11/2026
Fabric Insights and Fonn Group have announced a partnership to connect editorial...
17/11/2026
The National Association of Black Journalists is offering up a Thanksgiving Eve treat on Wednesday, Nov. 25, in the form of a live streaming event featuring for...
17/11/2026
Bridge Technologies has announced that its VB440 production probe now supports both monitoring and signal generation for Apple ProRes video streams. The additio...
17/11/2026
Canon U.S.A., Inc. recently welcomed 21 Jericho High School students to its Melv...
17/11/2026
Spectrum News has deployed the Amagi platform to support its live news operations. Amagi says the platform lets Spectrum News streamline newsroom workflows, red...
17/11/2026
Microsoft has expanded its use of Haivision's live video contribution ecosys...
17/11/2026
Setanta Sports has deployed Ateme's TITAN Live platform to support its OTT video delivery operations. Ateme's transcoding technology is integrated into ...
17/11/2026
Media Links has joined the KAIROS Alliance Partner program for Panasonic's KAIROS IT/IP live video production platform. The company completed interoperabili...
17/11/2026
Behind The Mic provides a roundup of recent news regarding on-air talent, including new deals, departures, and assignments compiled from press releases and repo...
17/11/2026
In live sports and in life, things go by in the blink of an eye. Savoring the mo...
17/11/2026
Satellite operators are adding a new generation of low-Earth-orbit (LEO) network...
17/11/2026
Clear-Com has delivered five customized test systems for electromagnetic securit...
17/11/2026
Stephen Arnold Music (SAM) has created the sonic identity for WTGL, the women's team golf league from TMRW Sports, created in partnership with the LPGA and ...
17/11/2026
The Professional Audio Manufacturers Alliance (PAMA) has introduced Give Sound a Voice, an initiative aimed at raising awareness of the value of sound among the...
17/11/2026
Fanatics Studios, the sports entertainment joint venture between Fanatics and OBB, has named Jamal Henderson its first President of Film & TV, announced Michael...
17/11/2026
The NFL's Thanksgiving Week games will feature halftime performances by U2, ...
17/11/2026
FanSided, a Minute brand with more than 250 fan communities, has launched a redesigned mobile app that combines team news, analysis, live game coverage, stats a...
17/11/2026
Major League Volleyball (MLV), the longest-running indoor professional volleybal...
17/11/2026
Prime Video will present a 15-hour slate of live sports on Black Friday, Nov. 27...
17/11/2026
Catherine Dior was more than a muse. A Resistance fighter, a survivor of deporta...
17/11/2026
Multiband dynamics plug-in boasts FT1 integration
Freqport's latest plug-in combines multiband upward and downward dynamics with the company's renow...
17/11/2026
Hi-fi experts launch two pro-audio models
Berlin-based hi-fi experts Teufel Audio have recently branched out into the pro-audio world with their first pairs...
17/11/2026
A year of ComposerCloud+ for $99
EastWest's annual Black Friday Sale is already live, and new users are being offered one year of the all-encompassing C...
17/11/2026
Pick your favourite gear from 2026
The annual SOS Awards are now underway, and as always, we're asking readers to help us choose the best pro-audio rele...
17/11/2026
As part of an ongoing series production program for a German automaker, production capacity has been increased at SGL Carbon's Austrian site in Ried im Innk...
17/11/2026
eds3_5_jq(document).ready(function($) { $(#eds_sliderM519).chameleonSlider_2_1({...
17/11/2026
Signiant has acquired the media intelligence technology, Ceivo, developed by Burnlab with founder Aaron Sloman joining the company as Vice President, Product Ma...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Berklees 2027 Alumni Grammy Nominees: See the Full List From pop and R&B to jazz, musical theater, and video game scores, Berklee talent is represented across...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
17/11/2026
LA JOLLA, CA-Two Scripps Research faculty, Assistant Professor Christian Diercks...
17/11/2026
Our Biggest Sale of the Year on Ivory 3!
From November 17th through November 30th, enjoy our best savings of the year on Ivory 3 Products!
Whether it's ou...
17/11/2026
Tuesday 17 November 2026
Sky announces major free upgrade to the Sky Glass and ...
17/11/2026
Tuesday 17 November 2026
Passion, Betrayal and Scandal: Sky Arts Reveals the Ma...
17/11/2026
Exact 3D Video, a web service based in Japan, has launched its English version, ...
17/11/2026
Today, Apple Podcasts named Baby, this is Keke Palmer its Show of the Year, hono...
17/11/2026
NVIDIA's Ian Buck kicked off the company's week at SC26 in Chicago on Monday with new tools for AI agents, software that can plan experiments, run code ...